17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2024 Mar 25

PMID 38523737

Authors

Bale Govardhan

V Kulkarni Anand

Padaki Nagaraja Rao

P Balachandran Menon

Sharma Mithun

Mitnala Sasikala

T R Sowmya

Sekaran Anuradha

C Pawar Smita

D Nageshwar Reddy

Vishnubhotla Ravikanth

Affiliations

Soon will be listed here.

Abstract

Background: A splice variant in gene is demonstrated to protect against nonalcoholic fatty liver disease (NAFLD), and mitigate the effect of Patatin-like phospholipase domain-containing 3 (-I148M). It is being explored as a putative drug target and in polygenic risk scores. Based on whole exome sequencing (WES) in our cohort of biopsy proven NAFLD and limited data on the variant in our ethnicity, we sought to explore its role.

Methods: This is a cross-sectional study that recruited 1,020 individuals with ultrasound/biopsy-confirmed NAFLD and matched controls. Liver enzymes and lipid profiles were estimated (Beckman coulter LX750/DXH800); WES was performed in NAFLD patients and controls (Illumina; HiSeqX); -A-INS/I148M- variants were genotyped (sequencing/qR T-PCR); HSD17B13 protein expression was estimated (immunohistochemistry); the Student's t-test/Mann-Whitney U/Chi-square test and odds ratio (95% confidence interval) were used.

Results: There was no significant difference (Odds ratio = 0.76; 95% CI -0.57 to 1.03; = 0.76) in the frequency of the rs72613567-A-INS between controls and patients (17.8% vs. 14.4%). No difference in the ALT (Alanine transaminase; 72.24 ± 65.13 vs. 73.70 ± 60.06; = 0.51) and AST levels (Aspartate aminotransferase; 60.72 ± 55.59 vs. 61.63 ± 60.33; = 0.91) between wild and variant carriers were noted. Significantly elevated liver enzymes were seen in -148-variant/wild compared with -148-variant/variant (90.44 ± 59.0 vs. 112.32 ± 61.78; = 0.02). No difference in steatosis ( = 0.51) between -wild and variant carriers was noted. No other variants in the intron-exon boundaries were identified. Although, protein expression differences were noted between wild and variant carriers, no difference in the extent of steatosis was seen.

Conclusion: Our study reports lack of association of the splice variant with reduced risk of NAFLD, and mitigating the effect of variant. Ethnicity-based validation must be carried out before including it in assessing protection against NAFLD.

References

Pennisi G, Enea M, Falco V, Aithal G, Palaniyappan N, Yilmaz Y . Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology. 2023; 78(1):195-211. DOI: 10.1097/HEP.0000000000000351. View

Meroni M, Longo M, Tria G, Dongiovanni P . Genetics Is of the Essence to Face NAFLD. Biomedicines. 2021; 9(10). PMC: 8533437. DOI: 10.3390/biomedicines9101359. View

Su W, Mao Z, Liu Y, Zhang X, Zhang W, Gustafsson J . Role of HSD17B13 in the liver physiology and pathophysiology. Mol Cell Endocrinol. 2018; 489:119-125. DOI: 10.1016/j.mce.2018.10.014. View

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View

Vilar-Gomez E, Pirola C, Sookoian S, Wilson L, Liang T, Chalasani N . The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. Clin Transl Gastroenterol. 2021; 12(9):e00400. PMC: 8437218. DOI: 10.14309/ctg.0000000000000400. View

Duseja A, Singh S, De A, Madan K, Rao P, Shukla A . Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Exp Hepatol. 2023; 13(2):273-302. PMC: 10025685. DOI: 10.1016/j.jceh.2022.11.014. View

Liu W, Eslam M, Zheng K, Ma H, Rios R, Lv M . Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol. 2021; 9(2):194-202. PMC: 8111109. DOI: 10.14218/JCTH.2020.00151. View

Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M . Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 2009; 50(3):772-80. DOI: 10.1002/hep.23094. View

Motomura T, Amirneni S, Diaz-Aragon R, Faccioli L, Malizio M, Coard M . Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target. J Pers Med. 2021; 11(7). PMC: 8304981. DOI: 10.3390/jpm11070619. View

10.

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F . Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015; 31(5):936-44. DOI: 10.1111/jgh.13264. View

11.

Vernon G, Baranova A, Younossi Z . Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34(3):274-85. DOI: 10.1111/j.1365-2036.2011.04724.x. View

12.

Gellert-Kristensen H, Nordestgaard B, Tybjaerg-Hansen A, Stender S . High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant. Hepatology. 2019; 71(1):56-66. DOI: 10.1002/hep.30799. View

13.

Anstee Q, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D . Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020; 73(3):505-515. DOI: 10.1016/j.jhep.2020.04.003. View

14.

LaBrecque D, Abbas Z, Anania F, Ferenci P, Khan A, Goh K . World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014; 48(6):467-73. DOI: 10.1097/MCG.0000000000000116. View

15.

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

16.

Dong X . A closer look at the mysterious HSD17B13. J Lipid Res. 2020; 61(11):1361-1362. PMC: 7604724. DOI: 10.1194/jlr.C120001160. View

17.

Wang M, Li J, Li H, Dong B, Jiang J, Liu N . Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2022; 23(10). PMC: 9146021. DOI: 10.3390/ijms23105544. View

18.

Ting Y, Kong A, Zain S, Chan W, Tan H, Mohamed Z . Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. Clin Mol Hepatol. 2021; 27(3):486-498. PMC: 8273635. DOI: 10.3350/cmh.2020.0162. View

19.

Anstee Q, Day C . The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10(11):645-55. DOI: 10.1038/nrgastro.2013.182. View

20.

Ghodsian N, Abner E, Emdin C, Gobeil E, Taba N, Haas M . Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med. 2021; 2(11):100437. PMC: 8606899. DOI: 10.1016/j.xcrm.2021.100437. View